New GranuFlo Lawsuit Website from Bernstein Liebhard LLP Provides Information on Growing Dialysis Recall Litigation and How to File a Claim against Fresenius
New York, NY (PRWEB) April 18, 2014 -- Bernstein Liebhard LLP has launched a new website for dialysis patients and families who were allegedly affected by the GranuFlo recall (http://www.granuflolawsuit2014.com/) of June 2012, and are now considering a claim against the drug’s manufacturer, the Firm reports.
Among other things, the Firm’s new site will provide updates on the growing litigation of claims against Fresenius Medical Care that allege sudden cardiac death, heart attacks, strokes, and other cardiovascular injuries following use of the medication. Court records show that many of these lawsuits are now pending in a federal litigation that also involves cases over NaturaLyte, another acid concentrate used in dialysis, and is now underway in the U.S. District Court, District of Massachusetts. Claims in this proceeding were filed after a recall in June 2012 by the U.S. Food and Drug Administration (FDA) that was categorized as Class I, the federal agency’s most serious type of recall. According to GranuFlo and NaturaLyte lawsuits now pending in federal court, alleged side effects of these medications are generally experienced within 72 hours of administration. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)
“As we actively file GranuFlo lawsuits on behalf of dialysis patients who allegedly experienced its serious and life-threatening side effects, our Firm recognizes the importance of providing a website for individuals who may be eligible to file a claim,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs including GranuFlo and NaturaLyte. The Firm is currently offering free and confidential case evaluations to individuals who may have experienced heart problems within 72 hours of receiving either of these medications.
GranuFlo Lawsuits
According to a Case List updated on April 15th by the U.S. Judicial Panel on Multidistrict Litigation (JPML), a total of 1,570 lawsuits over GranuFlo and NaturaLyte have now been filed in the District of Massachusetts. Plaintiffs in these federally-filed cases allege that they were improperly warned about side effects that may stem from the acid concentrates, which are administered in dialysis treatment centers operating in and outside the Fresenius network, prior to the FDA recall in June 2012. In addition to lawsuits filed in Massachusetts federal court, recent records show a number of claims now pending in Middlesex County Superior Court. (In re: Consolidated Fresenius Cases, No. MICV2013-03400-O)
These lawsuits similarly claim that an Urgent Product Notification from Fresenius on March 29, 2012 was issued too late, and that thousands of doctors had been administering GranuFlo and NaturaLyte to patients during that time without knowledge of their possible side effects. The company’s public health alert warned of the dialysis drugs’ high amount of an ingredient the body converts to bicarbonate, which may result in a condition known as metabolic alkalosis if the medications are dosed inappropriately. This condition may lead to elevated levels of bicarbonate in the blood stream, and cause serious cardiovascular problems, Fresenius said at the time.
A New York Times report published shortly after the FDA recall of GranuFlo and NaturaLyte suggests that the company may have known about side effects associated with the medications long before their March 2012 warning, which they concealed from the public. After learning of an internal memo sent by Fresenius in November 2011 that acknowledged 941 patient deaths that occurred in its dialysis clinics, the June 2012 report indicated that the FDA was investigating whether the company violated federal regulations by withholding safety information from the public. NaturaLyte and GranuFlo lawsuit plaintiffs now include that information in claims filed against Fresenius.*
Dialysis patients who allegedly experienced serious cardiovascular injuries stemming from these medications may be eligible to file lawsuits against Fresenius Medical Care. Learn more (http://www.granuflolawsuit2014.com/granuflo-dialysis-recall/) about the GranuFlo recall by visiting Bernstein Liebhard LLP’s website, or the Firm’s Facebook page: https://www.facebook.com/granuflolawsuit. For more information, and to arrange for a free case review, please call 800-511-5092.
*nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html; New York Times, June 14, 2012About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since the list was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.granuflolawsuit2014.com/
https://plus.google.com/115936073311125306742?rel=author
Felecia L. Stern, GranuFlo Dialysis Treatment Lawsuit Center, http://www.granuflolawsuit2014.com/, +1 800-511-5092, [email protected]
Share this article